VEGF and myeloid leukemias

Arthur E. Frankel, Parkash S. Gill

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Vascular endothelial growth factor and vascular endothelial growth factor receptors participate in the growth and survival of myeloid leukemic progenitors. With the development of multiple anti-angiogenic agents, there is potential that some of these novel agents will have anti-leukemic activity. Since these agents work by mechanisms distinct from current cytotoxic chemotherapies, they may be useful both in chemoresistant leukemia patients and in combinations to improve remission rates and remission durations.

Original languageEnglish (US)
Pages (from-to)675-677
Number of pages3
JournalLeukemia Research
Volume28
Issue number7
DOIs
StatePublished - Jul 2004

Fingerprint

Vascular Endothelial Growth Factor Receptor
Myeloid Leukemia
Vascular Endothelial Growth Factor A
Leukemia
Drug Therapy
Growth

Keywords

  • Myeloid leukemias
  • VEGF
  • VEGFR

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

VEGF and myeloid leukemias. / Frankel, Arthur E.; Gill, Parkash S.

In: Leukemia Research, Vol. 28, No. 7, 07.2004, p. 675-677.

Research output: Contribution to journalArticle

Frankel, Arthur E. ; Gill, Parkash S. / VEGF and myeloid leukemias. In: Leukemia Research. 2004 ; Vol. 28, No. 7. pp. 675-677.
@article{32e280ac845f422399d4081145755e2b,
title = "VEGF and myeloid leukemias",
abstract = "Vascular endothelial growth factor and vascular endothelial growth factor receptors participate in the growth and survival of myeloid leukemic progenitors. With the development of multiple anti-angiogenic agents, there is potential that some of these novel agents will have anti-leukemic activity. Since these agents work by mechanisms distinct from current cytotoxic chemotherapies, they may be useful both in chemoresistant leukemia patients and in combinations to improve remission rates and remission durations.",
keywords = "Myeloid leukemias, VEGF, VEGFR",
author = "Frankel, {Arthur E.} and Gill, {Parkash S.}",
year = "2004",
month = "7",
doi = "10.1016/j.leukres.2003.12.013",
language = "English (US)",
volume = "28",
pages = "675--677",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "7",

}

TY - JOUR

T1 - VEGF and myeloid leukemias

AU - Frankel, Arthur E.

AU - Gill, Parkash S.

PY - 2004/7

Y1 - 2004/7

N2 - Vascular endothelial growth factor and vascular endothelial growth factor receptors participate in the growth and survival of myeloid leukemic progenitors. With the development of multiple anti-angiogenic agents, there is potential that some of these novel agents will have anti-leukemic activity. Since these agents work by mechanisms distinct from current cytotoxic chemotherapies, they may be useful both in chemoresistant leukemia patients and in combinations to improve remission rates and remission durations.

AB - Vascular endothelial growth factor and vascular endothelial growth factor receptors participate in the growth and survival of myeloid leukemic progenitors. With the development of multiple anti-angiogenic agents, there is potential that some of these novel agents will have anti-leukemic activity. Since these agents work by mechanisms distinct from current cytotoxic chemotherapies, they may be useful both in chemoresistant leukemia patients and in combinations to improve remission rates and remission durations.

KW - Myeloid leukemias

KW - VEGF

KW - VEGFR

UR - http://www.scopus.com/inward/record.url?scp=2442550856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442550856&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2003.12.013

DO - 10.1016/j.leukres.2003.12.013

M3 - Article

C2 - 15158088

AN - SCOPUS:2442550856

VL - 28

SP - 675

EP - 677

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 7

ER -